- Home
- PRME
PRME
Prime Medicine Inc.
as 11-14-2025 3:43pm EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
| Founded: | 2019 | Country: | United States |
| Employees: | 214 | City: | CAMBRIDGE |
| Market Cap: | 601.1M | IPO Year: | 2022 |
| Target Price: | $9.31 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $6.94 | Next Earning Date: | 11-07-2025 |
| Revenue: | $5,977,000 | Revenue Growth: | 647.13% |
| Revenue Growth (this year): | 179.58% | Revenue Growth (next year): | -64.06% |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them.
GlobeNewswire
15 days ago
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
Zacks
15 days ago
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
4 months ago
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
MT Newswires
4 months ago
Prime Medicine Receives Up to $24 Million From Cystic Fibrosis Foundation
GlobeNewswire
4 months ago
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
GlobeNewswire
6 months ago
Prime Medicine to Participate in Upcoming Investor Conferences
Insider Monkey
6 months ago
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.